Related Experiment Video
Updated: Jun 2, 2026
09:55
Three-Dimensional Imaging of Aortic Tissues in Atherosclerosis
Published on: October 25, 2024
[Gastroenterological aspects of atherosclerosis]
Summary
Atherosclerosis pathogenesis involves dyslipidemia, gut dysbiosis, and liver dysfunction. Nonalcoholic fatty liver disease (NAFLD) exacerbates cardiovascular risk, necessitating hepatoprotectors alongside statins and fibrates.
Area of Science:
- Cardiovascular Science
- Hepatology
- Gastroenterology
Context:
- Atherosclerosis pathogenesis remains incompletely understood despite extensive research.
- Dyslipidemia is a primary risk factor for atherosclerosis and cardiovascular disease.
- Gut dysbiosis and endotoxemia contribute to liver dysfunction and cardiovascular risk.
Purpose:
- To explore the intricate relationship between dyslipidemia, gut microbiota, liver health, and atherosclerosis.
- To highlight the role of nonalcoholic fatty liver disease (NAFLD) as a cardiovascular risk factor.
- To discuss the therapeutic implications of hepatoprotectors in managing atherogenic dyslipidemia with NAFLD.
Summary:
- Atherogenic dyslipidemia triggers gut dysbiosis, leading to endotoxemia, bacterial translocation, and impaired liver function.
- The liver is central to atherogenic dyslipidemia and is a target organ for nonalcoholic fatty liver disease (NAFLD) development.
- NAFLD significantly increases cardiovascular risk and complicates lipid-lowering therapy, underscoring the need for hepatoprotective strategies.
Impact:
- Understanding these links can refine therapeutic strategies for atherosclerosis and related cardiovascular diseases.
- Hepatoprotective agents may offer a valuable adjunct therapy for patients with atherogenic dyslipidemia and NAFLD.
- Tailoring hepatoprotector selection based on NAFLD stage could optimize treatment outcomes and reduce cardiovascular events.
Related Concept Videos
01:30Atherosclerosis I: Introduction
Atherosclerosis is a progressive disorder characterized by the buildup of plaques on the arterial inner wall, causing them to narrow and harden over time. These plaques comprise lipids, calcium, blood components, carbohydrates, and fibrous tissue. The process primarily affects the intima of large and medium-sized arteries, reducing blood flow in any artery.Etiology and risk factorsThe cause of atherosclerosis is multifactorial, involving a complex interplay among endothelial injury, lipid...
01:17Gastritis-II: Pathophysiology
Gastritis is marked by disruption of the mucosal barrier that usually protects the stomach tissue from digestive juices and manifests in acute and chronic forms.
In acute gastritis, the gastric mucosa becomes swollen and red and undergoes superficial erosion. Superficial ulceration may lead to bleeding.
In chronic gastritis, persistent or repeated insults lead to chronic inflammatory changes and, eventually, thinning or atrophy of the gastric tissue.
Gastritis can stem from various causes, each...
In acute gastritis, the gastric mucosa becomes swollen and red and undergoes superficial erosion. Superficial ulceration may lead to bleeding.
In chronic gastritis, persistent or repeated insults lead to chronic inflammatory changes and, eventually, thinning or atrophy of the gastric tissue.
Gastritis can stem from various causes, each...
01:26Gastritis II: Pathophysiology
The pathophysiology of gastritis begins with the colonization of the stomach lining by Helicobacter pylori (H. pylori). This bacterium spreads mainly via the oral-oral route through saliva or shared utensils, and can also be transmitted in overcrowded or unhygienic environments through contaminated water, despite its brief survival outside the body.ColonizationOnce ingested, H. pylori enters the stomach and begins colonization by navigating through the mucus layer lining the stomach wall. It...
01:27Atherosclerosis II: Clinical Manifestations and Diagnostic Tests
Atherosclerosis is a progressive disorder that leads to the thickening and narrowing of arterial walls due to plaque buildup. This condition can cause various symptoms depending on the arteries affected:Coronary Artery Disease (CAD): This condition affects the coronary arteries and may lead to chest pain (angina), shortness of breath (dyspnea), heart attacks, and other heart disease symptoms.Cerebrovascular Disease: This affects blood flow to the brain, causing transient ischemic attacks (TIAs)...
01:26Atherosclerosis III: Management
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
01:26Coronary Artery Disease II: Pathophysiology
Coronary Artery Disease (CAD) originates from a series of events that impair the function of coronary arteries, the blood vessels responsible for delivering oxygen-rich blood to the heart muscle. The pathophysiology of CAD is closely linked to atherosclerosis, a chronic inflammatory and lipid-driven condition affecting the vascular endothelium.1. Endothelial DamageThe process begins with damage to the vascular endothelium, which serves as a protective barrier between the blood and the vessel...